Relyens Innovation Santé

Relyens Innovation Santé is a venture capital firm dedicated to supporting innovative companies in the healthcare sector. It focuses on businesses developing breakthrough medical technologies that address significant unmet medical needs, aiming to become leaders in their respective fields. The firm is controlled and owned by the Relyens Group, a mutual insurance company specializing in risk management for healthcare, social, and medical players. Advised by Turenne Santé, the health division of Turenne Group, Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.

The firm's investment strategy targets companies in the e-Health, MedTech, and BioTech sectors, with a particular emphasis on biopharmaceutical platforms, medical devices, diagnostics, and e-Health solutions. Relyens Innovation Santé seeks to invest in companies that are developing disruptive technologies in the medical field, addressing significant and unmet medical needs, and have the potential to become leaders in their sector.

Over the years, Relyens Innovation Santé has built a diverse portfolio of companies, including Dessintey, which specializes in intensive rehabilitation technologies for accelerating recovery and ensuring greater autonomy for patients. The firm has also been involved in significant funding rounds, such as leading a €20 million Series B financing for AlgoTx, a European biotech company developing treatments for chemotherapy-induced peripheral neuropathy. These investments reflect Relyens Innovation Santé's commitment to fostering innovation and supporting the growth of companies that aim to transform healthcare through technological advancements.